Expert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the development of ratutrelvir, a SARS-CoV-2 Main protease (Mpro) ...

A new publication in Nature Reviews Methods Primers provides essential guidance for conducting rigorous systematic reviews on ...

A new thought piece led by the Harvard Pilgrim Health Care Institute with collaborators from Duke University and Kaiser Permanente Washington Health Research Institute highlights the challenges facing ...

Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate ...

Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical trials, focusing on ...

The failure of clinical trials using gamma-secretase inhibitors ... the researchers will carry out more research on cellular homeostasis in the early phases of AD and will collaborate with colleagues ...

Car-T cell therapy has changed the face of many cancer treatments, but the level of customization it requires still comes ...

A new thought piece led by the Harvard Pilgrim Health Care Institute with collaborators from Duke University and Kaiser ...

The latest CorEvitas registry – the company’s 11th independent registry – will allow the prospective evaluation of adolescent AD patients to better understand the disease and the treatment pathway. It ...

Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.